Breaks Categories: News

WednesdayOct 21, 2020 10:53 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Forms New Scientific Advisory Board

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins, has announced  the formation of a Scientific Advisory Board (“SAB”) designed to provide the company with invaluable expertise and insights. The company also announced that three leading global experts in exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis have been appointed to the board: Michael Konstan, MD; Darwin L. Conwell, MD; and Michael Wilschanski, MD. Konstan is vice dean for translational research and the Gertrude Lee Chandler Tucker Professor of Pediatrics at Case Western Reserve University School of Medicine; he…

Continue Reading

TuesdayOct 20, 2020 10:06 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Completion of Manufacturing of Lead Drug Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has completed the manufacturing process for Berubicin Drug Product. CNSP’s U.S. manufacturer, Pharmaceutics International Inc. ("Pii"), has finished manufacturing the drug, which is the company’s lead drug candidate for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of incurable brain cancer. In an attempt to diversify its supply chain, provide for local accessibility of Berubicin and reduce COVID-19-related delay risks, CNS had implemented a dual-track drug product manufacturing approach that used two different manufacturers for…

Continue Reading

FridayOct 16, 2020 12:45 pm

BioMedNewsBreaks – KBL Merger Corp. IV (NASDAQ: KBLM) Featured in Seeking Alpha Article Discussing ‘Blockbuster Year for SPACs’

KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC) that previously announced the acquisition of 180 Life Sciences, was featured in a Seeking Alpha news article. The piece discussed a “blockbuster year for SPACs,” indicating that, to date, fiscal year 2020 has seen 127 SPAC IPOs collectively raise over $48.5 billion in proceeds. This represents significantly more than the previous ten years combined. The article covers the process of going public via a SPAC as a cost-effective way to complete a M&A deal in weeks instead…

Continue Reading

WednesdayOct 14, 2020 11:00 am

BioMedNewsBreaks – Oncocyte Corporation (NYSE American: OCX) Presents New DetermaRx(TM) Prospective Data at IASLC 2020 Conference

Oncocyte (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, is presenting new prospective data on DetermaRx(TM) at the IASLC 2020 North America Conference on Lung Cancer taking place on October 22. Gavitt Woodard, M.D., assistant professor, Yale School of Medicine, and lead author on the study is presenting the data at the event hosted by the International Association for the Study of Lung Cancer. Per the update, DetermaRx is a treatment stratification test that identifies stage I-IIA non-small cell lung cancer (“NSCLC”) patients at high-risk…

Continue Reading

WednesdayOct 14, 2020 10:44 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Adds More Sites for Cystic Fibrosis Clinical Trials

AzurRx BioPharma (NASDAQ: AZRX) has activated additional clinical trial sites for its trial of MS1819 in cystic fibrosis. The company specializes in the development of nonsystemic, recombinant therapies for gastrointestinal diseases. The company has activated two additional trial sites in Turkey for its Phase 2 combination therapy trial of its lead drug candidate, MS1819. MS1819 is a recombinant lipase for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients suffering from chronic pancreatitis and cystic fibrosis. Patient screening has already been initiated for the new trial sites, with topline data expected by Q2 2021. AzurRx had previously activated six clinical sites in Hungary,…

Continue Reading

TuesdayOct 13, 2020 1:05 pm

BioMedNewsBreaks – KBL Merger Corp. IV’s (NASDAQ: KBLM) S-4 Registration Statement Declared Effective by SEC, to Hold Special Meeting of Shareholders

KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC) that has signed a detailed merger agreement with 180 Life Sciences Corp., today announced that the U.S. Securities and Exchange Commission (the “SEC”) has declared effective the registration statement on Form S-4 (File No. 333-234650) it filed relating to the previously announced business combination with 180 Life Sciences (the “Business Combination”). According to the update, the company has commenced mailing the definitive proxy statement/prospectus relating to the Special Meeting (the “Special Meeting”) of the company’s stockholders to…

Continue Reading

TuesdayOct 13, 2020 12:38 pm

BioMedNewsBreaks – Lineage Cell Therapeutics Inc. (NYSE American: LCTX) (TASE: LCTX), Leading Cancer Charity Announce Encouraging Preliminary Phase 1 Study Results

Lineage Cell Therapeutics (NYSE American: LCTX) (TASE: LCTX) and Cancer Research UK have released encouraging results from an ongoing Phase 1 clinical study of VAC2 in non-small cell lung cancer (“NSCLC”). LCTX, a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, and Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research, worked together on the study, which focused on VAC2. Highlights of the study include potent induction of immune responses observed with the VAC2 vaccine and peripheral antigen-specific immunogenicity above 3% observed at multiple timepoints. In addition, VAC2 appeared to be well tolerated with…

Continue Reading

TuesdayOct 13, 2020 12:12 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Serial Entrepreneur as New Chief Operating Officer

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve survival and/or quality of life for patients who have high unmet medical needs, has appointed a new chief operating officer. Michael Floyd, a serial entrepreneur who has formed several life science organizations and served as a senior executive in those organizations, will be taking over that role. Floyd is well suited for the new position as many of the companies he has been involved in were focused on the development of products to treat infectious and rare diseases as well as the development of oncology drugs. Most recently,…

Continue Reading

TuesdayOct 13, 2020 11:20 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Platform Selected for Integration in Vitality’s Gateway Flex

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, today announced that Vitality Group has chosen the company's digital therapeutics solutions for inclusion in Vitality's new Gateway Flex offering. According to the update, Gateway Flex enables employers to personalize the health-care experience to meet the diverse and rapidly changing needs of their employees and allows employers to pay only for solutions in which their employees engage. “We believe that our inclusion in Vitality's Gateway Flex offering represents another recent validation of our digital therapeutic solution and reinforces our position as a partner of choice,” Rick Anderson, president and general…

Continue Reading

MondayOct 12, 2020 12:58 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. Files Registration Statement for Proposed $20M Initial Public Offering

Vivos Therapeutics, a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, on Friday announced that is has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to the proposed initial public offering of its common stock. According to the update, application has been made for listing the common stock on the Nasdaq Capital Market under the ticker symbol “VVOS.” The proposed $20,000,000 offering (not including the underwriters’ over-allotment option), which is subject to market conditions with no assurance as to its actual completion or terms, has…

Continue Reading